Insmed Reports Q3 2026 Revenue Growth of 268% Driven by BRINSUPRI Launch
Insmed (INSM) reported a significant surge in third-quarter 2026 revenue, totaling $524.4 million, which represents a 268% increase year-over-year. This explosive growth was primarily fueled by the successful commercial launch of BRINSUPRI, which contributed $400.1 million to the quarterly total. Despite a net loss of $100.3 million, the company showed improved financial health compared to the previous year's much larger loss, aided by favorable gross margins. Following these strong results, management raised full-year revenue guidance for both BRINSUPRI and ARIKAYCE. The company is also looking toward long-term growth through its TPIP pipeline and potential label expansions in 2027. While the Inflation Reduction Act (IRA) will increase manufacturer coverage costs in 2027, management expects this to expand gross-to-net margins for ARIKAYCE.
Topics: financial guidance net loss reduction product launch revenue growth